Inflammatix, Inc.

Watch this SelectScience® video interview with our CEO Tim Sweeney to better understand the necessity of addressing two key challenges in diagnosing and accurately treating infections: 1) Identifying pathogens, and 2) having a test that’s sensitive and specific enough to identify a type of infection as well as its severity. You will also learn about Tim’s journey from his post-doc at Stanford University to co-founding Inflammatix, and watch how the company’s Triverity™ Test and Myrna™ instrument work to address the aforementioned challenges. See this link and watch the video! https://lnkd.in/g-s8W9YA #sepsis #healthcare #diagnostics #InfectiousDiseases The TriVerity Test System is not for sale. It is currently pending FDA clearance and has not received marketing approval or clearance from regulatory authorities in any jurisdiction.

**Harnessing the Power of Bioinformatics to Decipher Immune Response**   As explained in The New York Times opinion piece by critical care expert Daniela Lamas, MD, inflammation is both a marker and driver of many common disorders, including heart disease and memory loss. Yet the dire consequences of #inflammation are not the whole story; indeed, our immune system can also mount an inflammatory response to protect us against infectious bacterial and viral intruders.     Our technology is derived from the complex interplay between the immune system and both the salutary and harmful effects of inflammation. We deploy advanced #bioinformatics to decode the body’s immune response to different types of diseases, using patient messenger RNA (mRNA) expression patterns to classify key disease markers.   We then use that information to develop diagnostics that detect these disease states early and with high accuracy. Our evidence-based diagnostics are designed to empower healthcare providers to make treatment decisions quickly and confidently.   The future of healthcare lies in deciphering the immune system’s signals—and we are proud to be at the forefront of advancing that understanding. #Immunology #Diagnostics #HealthcareInnovation https://lnkd.in/dN_irKBy Inflammatix products are not for sale and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.   

That’s a wrap! We had a blast at IDWeek engaging with ID physicians while in LA. The data we shared show that the TriVerity™ Test identified patients who would progress to ICU level care within 7 days, despite being initially rated as low-risk by conventional measures. We appreciate our staff who worked hard to educate ID professionals about our medical technology and how it will impact the future of ED patient care. Thank you to our attendees (pictured from left to right) Chad Brueck Natalie N. Whitfield, Ph.D., D(ABMM), FACSc, BCMAS Ashley Prasse Miller Jonathan Romanowsky Sam Ajizian MD. If you weren’t able to attend ACEP or ID Week, but would like a demo, hear more about our latest data, and/or have any questions, DM us to set up a time to chat! The TriVerity Test System is not for sale. It is currently pending FDA clearance and has not received marketing approval or clearance from regulatory authorities in any jurisdiction.

With our team rapidly growing we recently brought everyone together for a staff picnic. The break was much appreciated, and we were fortunate to have beautiful weather. Tawny Darling, our VP of people operations, said, "It was great to see our team come together after working so hard over these past few months to have some fun and get to know one another outside of the office." Thank you, Tawny! Kudos also to organizing committee members Christos Kampouridis, Mikaela Nicole Alganes, and Heidi Chung.

As recently covered in CAP TODAY by senior editor Amy Carpenter Aquino, emergency physicians often lack the diagnostic tools to accurately determine the presence, type, and severity of infections for patients presenting with undifferentiated symptoms, comorbidities, or complex symptoms. The good news is that innovation in host response detection can enable more rapid decision-making in the acute care setting, including detection of #sepsis. Our approach uses #bioinformatics and AI-driven models to enable rapid profiling of patient #hostresponse from blood samples, transforming insights to #pointofcare use for identifying patients’ likelihood of mortality, development of chronic critical illness, and/or secondary infections, and more. We’re proud to be on the forefront of #MedTech in this emerging era of infection care. #diagnostics #bioinformatics #HealthcareInnovation Inflammatix products are not for sale and do not have marketing approval or clearance from regulatory authorities in any jurisdiction. https://lnkd.in/gbr-m_ES  

We are humbled to win our second product design award in as many months. Thank you to Red Dot Design Award, one of the world’s largest design competitions, for recognizing the uniqueness of our TriVerity™ cartridge and Myrna™ instrument.   A big congrats to Inflammatix product designer Chris Wilson and team lead Paul Fleming, recognized for combining simplicity with advanced machine learning to enable prompt infection diagnosis and management. #HealthcareInnovation See here: https://lnkd.in/eNPPdxW4 The products referenced herein are not for sale. They are currently pending FDA clearance and have not received marketing approval or clearance from regulatory authorities in any jurisdiction.

Thank you Law360 for recognizing our new General Counsel Laura Spencer Garth, along with our other two new leadership team members, Chief Medical Officer Sam Ajizian MD and Chief Commercial Officer Jamie Lewis. At Inflammatix, our people are our secret power!   #HealthcareInnovation #Leadership https://lnkd.in/ezcpX3Ci

Today we formally announce the addition of three executives to our leadership team – Chief Medical Officer Sam Ajizian MD, Chief Commercial Officer Jamie Lewis, and General Counsel Laura Spencer Garth. Each is an expert in their respective areas, with extensive experience in bringing innovative medical technologies to market. #diagnostics #HealthcareInnovation These additions round out our leadership team in charge of commercializing TriVerity™ upon clearance. See today’s press release: https://lnkd.in/eQrJ-NTq Read more about our expanded leadership team at https://lnkd.in/eSmBzB6J The TriVerity Test is not for sale. It is currently pending FDA clearance and has not received marketing approval or clearance from regulatory authorities in any jurisdiction.

We’re gearing up for IDWeek, October 16-19 in Los Angeles! ID professionals are invited to our Booth #143 for a live demo of the TriVerity™ Test, and to learn about the vast potential of advanced, host-response diagnostics. We will also be presenting data from a multicenter observational study using TriVerity to predict 7-day ICU-level care (mechanical ventilation, vasopressors, and/or renal replacement therapy), in patients presenting to the emergency department with suspected acute infections or sepsis, compared to initial physician judgment and qSOFA. POSTER TITLE ** (P-2238) A Novel Transcriptomic-based Host Response Point-of-care Test to Distinguish Bacterial from Viral Infection: Results of a Diagnostic Accuracy Study in Adults Hospitalised with Acute Respiratory Illness** Saturday, October 19, 2024 12:15 PM – 1:30 PM US PT Location: Halls JK Presented by Bilge Eylem Dedeoglu, MD University Hospital Southampton NHS Foundation Trust See you in LA! #IDWeek24 #HostResponse #EmergencyMedicine #Diagnostics The TriVerity Test System is not for sale. It is currently pending FDA clearance and has not received marketing approval or clearance from regulatory authorities in any jurisdiction.

The threat of antimicrobial resistance was top-of-mind during the recent 79th session of the United Nations General Assembly (UNGA79). Global collaboration in improving systems for identifying and managing infectious disease is key to reducing this threat. The strengths and weaknesses of blood culturing, the standard for diagnosing bloodstream infections for more than 50 years, are clearly articulated in The Lancet opinion piece, ”Changing the Culture of Blood Culture.” As noted by the authors, the current shortage of blood-culture media bottles exemplifies one such weakness. Today, we are making progress in the innovation of culture-independent diagnostics. By “reading” the immune system’s reaction to infection, host response testing can differentiate bacterial infections from viruses, enabling healthcare providers to get patients the care they need quickly and accurately. Addressing the global scourge of antimicrobial resistance is a key focus of the UNGA, and initiatives are needed to further the development and implementation of more efficient and accurate diagnostic methods for infectious disease, including culture-independent diagnostics and reimbursement programs. The Lancet article: https://shorturl.at/j7VZ6 UNGA High-Level Meeting on antimicrobial resistance 2024: https://shorturl.at/8Ga5c Inflammatix products are not for sale and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.